Raffaele De Caterina

List of Publications by Citations

Source: https://exaly.com/author-pdf/7964955/raffaele-de-caterina-publications-by-citations.pdf

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

63 287 170 29,454 h-index g-index citations papers 6.1 6.76 34,294 335 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
287	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal, 2016 , 37, 2893-2962	9.5	4465
286	Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2010 , 31, 2369-429	9.5	3452
285	2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. <i>European Heart Journal</i> , 2012 , 33, 2719-47	9.5	2638
284	Universal definition of myocardial infarction. <i>Circulation</i> , 2007 , 116, 2634-53	16.7	1953
283	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>Europace</i> , 2016 , 18, 1609-1678	3.9	1293
282	2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. <i>Europace</i> , 2012 , 14, 1385-413	3.9	1019
281	Fourth universal definition of myocardial infarction (2018) European Heart Journal, 2019 , 40, 237-269	9.5	851
280	Apixaban with antiplatelet therapy after acute coronary syndrome. <i>New England Journal of Medicine</i> , 2011 , 365, 699-708	59.2	765
279	Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. <i>Cardiovascular Research</i> , 2004 , 63, 582-92	9.9	657
278	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Journal of Cardio-thoracic Surgery</i> , 2016 , 50, e1-e88	3	589
277	Olive oil and red wine antioxidant polyphenols inhibit endothelial activation: antiatherogenic properties of Mediterranean diet phytochemicals. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003 , 23, 622-9	9.4	504
276	Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. <i>Circulation</i> , 2002 , 105, 816-22	16.7	454
275	n-3 fatty acids in cardiovascular disease. New England Journal of Medicine, 2011, 364, 2439-50	59.2	446
274	Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic eventsEuropean Registry in Atrial Fibrillation (PREFER in AF). <i>Europace</i> , 2014 , 16, 6-14	3.9	283
273	Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on ThrombosisTask Force on Anticoagulants in Heart Disease. <i>Thrombosis and Haemostasis</i> , 2013 , 110, 1087-107	7	278
272	Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. <i>European Heart Journal</i> , 2011 , 32, 1854-64	9.5	273
271	Stroke prevention in atrial fibrillation: Past, present and future. Comparing the guidelines and practical decision-making. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 1230-1239	7	265

(2015-2014)

270	Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. <i>Journal of the American College of Cardiology</i> ,	15.1	260
269	2014 , 63, 2141-2147 Recommendations for the management of patients after heart valve surgery. <i>European Heart Journal</i> , 2005 , 26, 2463-71	9.5	260
268	Mediterranean diet polyphenols reduce inflammatory angiogenesis through MMP-9 and COX-2 inhibition in human vascular endothelial cells: a potentially protective mechanism in atherosclerotic vascular disease and cancer. <i>Archives of Biochemistry and Biophysics</i> , 2012 , 527, 81-9	4.1	238
267	Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. <i>European Heart Journal</i> , 2014 , 35, 1864-72	9.5	237
266	Orthostatic Hypotension: Epidemiology, Prognosis, and Treatment. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 848-860	15.1	229
265	Awake systolic blood pressure variability correlates with target-organ damage in hypertensive subjects. <i>Hypertension</i> , 2007 , 50, 325-32	8.5	216
264	Soluble vascular cell adhesion molecule-1 as a biohumoral correlate of atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997 , 17, 2646-54	9.4	212
263	New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 1413-25	15.1	211
262	Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. <i>Circulation</i> , 2014 , 130, 1847-	16.7 58	188
261	Cardiovascular morbidity and mortality related to orthostatic hypotension: a meta-analysis of prospective observational studies. <i>European Heart Journal</i> , 2015 , 36, 1609-17	9.5	168
260	At least 2 distinct pathways generating reactive oxygen species mediate vascular cell adhesion molecule-1 induction by advanced glycation end products. <i>Arteriosclerosis, Thrombosis, and Vascular Biology,</i> 2005 , 25, 1401-7	9.4	168
259	Oleic acid inhibits endothelial activation: A direct vascular antiatherogenic mechanism of a nutritional component in the mediterranean diet. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999 , 19, 220-8	9.4	166
258	Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. <i>Circulation</i> , 2013 , 127, 2166-76	16.7	164
257	Antiplatelet agents for the treatment and prevention of atherothrombosis. <i>European Heart Journal</i> , 2011 , 32, 2922-32	9.5	160
256	Estrogens and glucocorticoids inhibit endothelial vascular cell adhesion molecule-1 expression by different transcriptional mechanisms. <i>Circulation Research</i> , 2000 , 87, 19-25	15.7	159
255	From asthma to atherosclerosis5-lipoxygenase, leukotrienes, and inflammation. <i>New England Journal of Medicine</i> , 2004 , 350, 4-7	59.2	140
254	General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. <i>Thrombosis and Haemostasis</i> , 2013 , 109, 569-79	7	134
253	Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2015 , 36, 3238-49	9.5	129

252	Adipose tissue-derived stem cells: characterization and potential for cardiovascular repair. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009 , 29, 1723-9	9.4	126
251	Endothelial permeability, LDL deposition, and cardiovascular risk factors-a review. <i>Cardiovascular Research</i> , 2018 , 114, 35-52	9.9	125
250	Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 319-27	15.1	123
249	Cellular and molecular mechanisms of vascular injury in diabetespart I: pathways of vascular disease in diabetes. <i>Vascular Pharmacology</i> , 2011 , 54, 68-74	5.9	108
248	Control of endothelial leukocyte adhesion molecules by fatty acids. <i>Lipids</i> , 1996 , 31 Suppl, S57-63	1.6	108
247	Low-density lipoprotein level reduction by the 3-hydroxy-3-methylglutaryl coenzyme-A inhibitor simvastatin is accompanied by a related reduction of F2-isoprostane formation in hypercholesterolemic subjects: no further effect of vitamin E. <i>Circulation</i> , 2002 , 106, 2543-9	16.7	102
246	Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. <i>Annals of Internal Medicine</i> , 2011 , 155, 579-86	8	97
245	Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. <i>Circulation</i> , 2017 , 135, 1273-1275	16.7	94
244	Homocysteine induces VCAM-1 gene expression through NF-kappaB and NAD(P)H oxidase activation: protective role of Mediterranean diet polyphenolic antioxidants. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007 , 293, H2344-54	5.2	94
243	Anticoagulants in heart disease: current status and perspectives. European Heart Journal, 2007, 28, 880)-9313	94
243 242	Anticoagulants in heart disease: current status and perspectives. <i>European Heart Journal</i> , 2007 , 28, 880 Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub-Analysis From the PREFER in AF (vention o Thromboembolic Events-uropean egistry in trial ibrillation). <i>Journal of the American Heart</i>)-9j13 6	94 93
	Anticoagulants in heart disease: current status and perspectives. <i>European Heart Journal</i> , 2007 , 28, 880 Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub-Analysis From the PREFER in AF (vention o		
242	Anticoagulants in heart disease: current status and perspectives. <i>European Heart Journal</i> , 2007 , 28, 880 Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub-Analysis From the PREFER in AF (vention o Thromboembolic Events-uropean egistry in trial ibrillation). <i>Journal of the American Heart Association</i> , 2017 , 6, n-3 fatty acids in the treatment of diabetic patients: biological rationale and clinical data. <i>Diabetes</i>	6	93
242	Anticoagulants in heart disease: current status and perspectives. <i>European Heart Journal</i> , 2007 , 28, 880. Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub-Analysis From the PREFER in AF (vention o Thromboembolic Events-uropean egistry in trial ibrillation). <i>Journal of the American Heart Association</i> , 2017 , 6, n-3 fatty acids in the treatment of diabetic patients: biological rationale and clinical data. <i>Diabetes Care</i> , 2007 , 30, 1012-26 Nutritional mechanisms that influence cardiovascular disease. <i>American Journal of Clinical Nutrition</i> ,	6	93
242 241 240	Anticoagulants in heart disease: current status and perspectives. <i>European Heart Journal</i> , 2007 , 28, 880 Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub-Analysis From the PREFER in AF (vention o Thromboembolic Events-uropean egistry in trial ibrillation). <i>Journal of the American Heart Association</i> , 2017 , 6, n-3 fatty acids in the treatment of diabetic patients: biological rationale and clinical data. <i>Diabetes Care</i> , 2007 , 30, 1012-26 Nutritional mechanisms that influence cardiovascular disease. <i>American Journal of Clinical Nutrition</i> , 2006 , 83, 421S-426S Hydroxytyrosol suppresses MMP-9 and COX-2 activity and expression in activated human	6 14.6 7	93 93 92
242241240239	Anticoagulants in heart disease: current status and perspectives. <i>European Heart Journal</i> , 2007, 28, 880. Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub-Analysis From the PREFER in AF (vention o Thromboembolic Events-uropean egistry in trial ibrillation). <i>Journal of the American Heart Association</i> , 2017, 6, n-3 fatty acids in the treatment of diabetic patients: biological rationale and clinical data. <i>Diabetes Care</i> , 2007, 30, 1012-26 Nutritional mechanisms that influence cardiovascular disease. <i>American Journal of Clinical Nutrition</i> , 2006, 83, 421S-426S Hydroxytyrosol suppresses MMP-9 and COX-2 activity and expression in activated human monocytes via PKCIand PKCII inhibition. <i>Atherosclerosis</i> , 2014, 232, 17-24 Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular	6 14.6 7 3.1	93 93 92 88
242241240239238	Anticoagulants in heart disease: current status and perspectives. <i>European Heart Journal</i> , 2007, 28, 880 Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub-Analysis From the PREFER in AF (vention o Thromboembolic Events-uropean egistry in trial ibrillation). <i>Journal of the American Heart Association</i> , 2017, 6, n-3 fatty acids in the treatment of diabetic patients: biological rationale and clinical data. <i>Diabetes Care</i> , 2007, 30, 1012-26 Nutritional mechanisms that influence cardiovascular disease. <i>American Journal of Clinical Nutrition</i> , 2006, 83, 421S-426S Hydroxytyrosol suppresses MMP-9 and COX-2 activity and expression in activated human monocytes via PKC[and PKC[i inhibition. <i>Atherosclerosis</i> , 2014, 232, 17-24 Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1363-1371 Distal embolization during primary angioplasty: histopathologic features and predictability.	6 14.6 7 3.1 15.1	93 93 92 88 84

(2011-2010)

234	Nutraceuticals and prevention of atherosclerosis: focus on omega-3 polyunsaturated fatty acids and Mediterranean diet polyphenols. <i>Cardiovascular Therapeutics</i> , 2010 , 28, e13-9	3.3	74
233	Angina pectoris and myocardial ischemia in the absence of obstructive coronary artery disease: practical considerations for diagnostic tests. <i>JACC: Cardiovascular Interventions</i> , 2014 , 7, 453-63	5	73
232	Vasculoprotective potential of olive oil components. <i>Molecular Nutrition and Food Research</i> , 2007 , 51, 1225-34	5.9	73
231	Simvastatin attenuates expression of cytokine-inducible nitric-oxide synthase in embryonic cardiac myoblasts. <i>Journal of Biological Chemistry</i> , 2005 , 280, 13503-11	5.4	73
230	Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. <i>Lancet, The</i> , 2020 , 396, 1745-1757	40	70
229	Gender differences in clinical presentation and 1-year outcomes in atrial fibrillation. <i>Heart</i> , 2017 , 103, 1024-1030	5.1	66
228	The first 3500 years of aspirin history from its roots - A concise summary. <i>Vascular Pharmacology</i> , 2019 , 113, 1-8	5.9	65
227	Diabetic microangiopathy: Pathogenetic insights and novel therapeutic approaches. <i>Vascular Pharmacology</i> , 2017 , 90, 1-7	5.9	64
226	Awake blood pressure variability, inflammatory markers and target organ damage in newly diagnosed hypertension. <i>Hypertension Research</i> , 2008 , 31, 2137-46	4.7	63
225	Increased glycated albumin and decreased esRAGE levels are related to angiographic severity and extent of coronary artery disease in patients with type 2 diabetes. <i>Atherosclerosis</i> , 2009 , 206, 540-5	3.1	62
224	The dynamics of the coronary collateral circulation. <i>Nature Reviews Cardiology</i> , 2014 , 11, 191-7	14.8	61
223	Late thrombosis after double versus single drug-eluting stent in the treatment of coronary bifurcations: a meta-analysis of randomized and observational Studies. <i>JACC: Cardiovascular Interventions</i> , 2013 , 6, 687-95	5	61
222	Quenching of Intracellular ROS Generation as a Mechanism for Oleate-Induced Reduction of Endothelial Activation and Early Atherogenesis. <i>Thrombosis and Haemostasis</i> , 2002 , 88, 335-344	7	61
221	Antiarrhythmic effects of omega-3 fatty acids: from epidemiology to bedside. <i>American Heart Journal</i> , 2003 , 146, 420-30	4.9	57
220	C1q/TNF-related protein-1: an adipokine marking and promoting atherosclerosis. <i>European Heart Journal</i> , 2016 , 37, 1762-71	9.5	55
219	Determinants of long-term clinical outcomes in patients with angina but without obstructive coronary artery disease: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2018 , 39, 2135-	2146	54
218	High glucose-induced hyperosmolarity contributes to COX-2 expression and angiogenesis: implications for diabetic retinopathy. <i>Cardiovascular Diabetology</i> , 2016 , 15, 18	8.7	53
217	Increased serum high-mobility group box-1 and cleaved receptor for advanced glycation endproducts levels and decreased endogenous secretory receptor for advanced glycation endproducts levels in diabetic and non-diabetic patients with heart failure. Furgingal Journal of	12.3	51

216	Rapid decline of collateral circulation increases susceptibility to myocardial ischemia: the trade-off of successful percutaneous recanalization of chronic total occlusions. <i>Journal of the American College of Cardiology</i> , 2006 , 48, 59-65	15.1	51
215	Antioxidant and Anti-Inflammatory Properties of Oil in Human Pre-Adipocytes. <i>Antioxidants</i> , 2019 , 8,	7.1	49
214	Effects of omega-3 fatty acids on cytokines and adhesion molecules. <i>Current Atherosclerosis Reports</i> , 2004 , 6, 485-91	6	47
213	Insulin-Requiring Versus Noninsulin-Requiring Diabetes and Thromboembolic Risk in Patients With Atrial Fibrillation: PREFER in AF. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 409-419	15.1	46
212	Genetic determinants of blood pressure responses to caffeine drinking. <i>American Journal of Clinical Nutrition</i> , 2012 , 95, 241-8	7	46
211	Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48. Clinical Cardiology, 2016 , 39, 345-6	3.3	46
210	Transplantation of adipose tissue mesenchymal cells conjugated with VEGF-releasing microcarriers promotes repair in murine myocardial infarction. <i>Cardiovascular Research</i> , 2015 , 108, 39-49	9.9	45
209	Long-term use of anti-inflammatory drugs and risk of atrial fibrillation. <i>Archives of Internal Medicine</i> , 2010 , 170, 1450-5		44
208	Glycaemic control in acute coronary syndromes: prognostic value and therapeutic options. <i>European Heart Journal</i> , 2010 , 31, 1557-64	9.5	44
207	Complete myocardial revascularization confers a larger clinical benefit when performed with state-of-the-art techniques in high-risk patients with multivessel coronary artery disease: A meta-analysis of randomized and observational studies. <i>Catheterization and Cardiovascular</i>	2.7	43
206	Circulating endothelial progenitor cells: Do they live up to their name?. <i>Vascular Pharmacology</i> , 2015 , 67-69, 2-5	5.9	43
205	Extra virgin olive oil rich in polyphenols modulates VEGF-induced angiogenic responses by preventing NADPH oxidase activity and expression. <i>Journal of Nutritional Biochemistry</i> , 2016 , 28, 19-29	6.3	41
204	Cellular and molecular mechanisms of vascular injury in diabetespart II: cellular mechanisms and therapeutic targets. <i>Vascular Pharmacology</i> , 2011 , 54, 75-9	5.9	41
203	n-3 fatty acids: antiatherosclerotic effects. <i>Lipids</i> , 2001 , 36 Suppl, S69-78	1.6	41
202	The left atrial appendage: from embryology to prevention of thromboembolism. <i>European Heart Journal</i> , 2017 , 38, 877-887	9.5	41
201	The Extra-Virgin Olive Oil Polyphenols Oleocanthal and Oleacein Counteract Inflammation-Related Gene and miRNA Expression in Adipocytes by Attenuating NF-B Activation. <i>Nutrients</i> , 2019 , 11,	6.7	41
200	The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review. <i>Clinical Research in Cardiology</i> , 2017 , 106, 565-572	6.1	40
199	Additive regulation of adiponectin expression by the mediterranean diet olive oil components oleic Acid and hydroxytyrosol in human adipocytes. <i>PLoS ONE</i> , 2015 , 10, e0128218	3.7	38

(2007-2019)

198	Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. <i>Nature Reviews Cardiology</i> , 2019 , 16, 113-130	14.8	37
197	Strong association of the APOA5-1131T>C gene variant and early-onset acute myocardial infarction. <i>Atherosclerosis</i> , 2011 , 214, 397-403	3.1	36
196	Endothelial dysfunctions: common denominators in vascular disease. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2000 , 3, 453-67	3.8	36
195	Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR)仰gonist aleglitazar in attenuating TNF-Emediated inflammation and insulin resistance in human adipocytes. <i>Pharmacological Research</i> , 2016 , 107, 125-136	10.2	35
194	Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation. <i>American Journal of Medicine</i> , 2019 , 132, 749-757.e5	2.4	34
193	Relevance of new drug discovery to reduce NF-B activation in cardiovascular disease. <i>Vascular Pharmacology</i> , 2012 , 57, 41-7	5.9	34
192	Innate and adaptive immunity in atherosclerosis. Vascular Pharmacology, 2018, 107, 67-67	5.9	32
191	Parenteral anticoagulants in heart disease: current status and perspectives (Section II). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. <i>Thrombosis and Haemostasis</i> , 2013 , 109, 769-86	7	31
190	Prolonged exposure to high insulin impairs the endothelial PI3-kinase/Akt/nitric oxide signalling. <i>Thrombosis and Haemostasis</i> , 2009 , 101, 345-350	7	31
189	Inflammation and thrombosis - testing the hypothesis with anti-inflammatory drug trials. <i>Thrombosis and Haemostasis</i> , 2016 , 116, 1012-1021	7	30
188	Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF). <i>BMJ Open</i> , 2019 , 9, e022478	3	29
187	Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials. <i>American Journal of Medicine</i> , 2015 , 128, 1007-14.e2	2.4	29
186	Impact of Sex Differences and Diabetes on Coronary Atherosclerosis and Ischemic Heart Disease. Journal of Clinical Medicine, 2019 , 8,	5.1	28
185	Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial. <i>Europace</i> , 2016 , 18, 6-11	3.9	27
184	Selective inhibition of thromboxane-related platelet function by low-dose aspirin in patients after myocardial infarction. <i>American Journal of Cardiology</i> , 1985 , 55, 589-90	3	27
183	Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF - HF substudy. <i>International Journal of Cardiology</i> , 2018 , 265, 141-147	3.2	26
182	Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. <i>European Heart Journal</i> , 2010 , 31, 2133-40	9.5	26
181	Both vitamin B6 and total homocysteine plasma levels predict long-term atherothrombotic events in healthy subjects. <i>European Heart Journal</i> , 2007 , 28, 484-91	9.5	26

180	The epicardial adipose tissue and the coronary arteries: dangerous liaisons. <i>Cardiovascular Research</i> , 2019 , 115, 1013-1025	9.9	25
179	Diabetic macroangiopathy: Pathogenetic insights and novel therapeutic approaches with focus on high glucose-mediated vascular damage. <i>Vascular Pharmacology</i> , 2018 ,	5.9	25
178	Hydroxytyrosol Modulates Adipocyte Gene and miRNA Expression Under Inflammatory Condition. <i>Nutrients</i> , 2019 , 11,	6.7	25
177	High glucose-induced hyperosmolarity impacts proliferation, cytoskeleton remodeling and migration of human induced pluripotent stem cells via aquaporin-1. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014 , 1842, 2266-75	6.9	25
176	Insulin potentiates cytokine-induced VCAM-1 expression in human endothelial cells. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2008 , 1782, 511-6	6.9	25
175	Elevated glycated albumin and reduced endogenous secretory receptor for advanced glycation endproducts levels in serum predict major adverse cardio-cerebral events in patients with type 2 diabetes and stable coronary artery disease. <i>International Journal of Cardiology</i> , 2015 , 197, 241-7	3.2	23
174	111In platelet scintigraphy for the noninvasive detection of carotid plaque thrombosis. <i>Stroke</i> , 2001 , 32, 719-27	6.7	23
173	Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) pilot study. <i>American Heart Journal</i> , 2004 , 148, e6	4.9	22
172	Non-Vitamin K Antagonist Oral Anticoagulants for Mechanical Heart Valves: Is the Door Still Open?. <i>Circulation</i> , 2018 , 138, 1356-1365	16.7	22
171	Effect of High-Dose Atorvastatin Reload on the Release of Endothelial Progenitor Cells in Patients on Long-Term Statin Treatment Who Underwent Percutaneous Coronary Intervention (from the ARMYDA-EPC Study). <i>American Journal of Cardiology</i> , 2016 , 117, 165-71	3	21
170	Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina. <i>Cardiovascular Diabetology</i> , 2019 , 18, 144	8.7	21
169	Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease. <i>Thrombosis and Haemostasis</i> , 2016 , 115, 685-711	7	21
168	Genetic determinants of cognitive responses to caffeine drinking identified from a double-blind, randomized, controlled trial. <i>European Neuropsychopharmacology</i> , 2015 , 25, 798-807	1.2	20
167	Prognostic Role of Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Low-to-Intermediate Sudden Cardiac Death Risk Score. <i>American Journal of Cardiology</i> , 2019 , 124, 1286-1292	3	20
166	Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe. <i>Heart</i> , 2014 , 100, 1625-35	5.1	20
165	Involvement of the TP receptor in TNF-Induced endothelial tissue factor expression. <i>Vascular Pharmacology</i> , 2014 , 62, 49-56	5.9	20
164	The new oral anticoagulants in atrial fibrillation: once daily or twice daily?. <i>Vascular Pharmacology</i> , 2013 , 59, 53-62	5.9	20
163	Ranolazine in the prevention of anthracycline cardiotoxicity. <i>Pharmacological Research</i> , 2014 , 79, 88-102	210.2	20

162	Isolated troponin increase after percutaneous coronary interventions: does it have prognostic relevance?. <i>Atherosclerosis</i> , 2012 , 221, 297-302	3.1	20	
161	Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 1145-1155	15.1	19	
160	Heart failure due to right ventricular apical pacing: the importance of flow patterns. <i>Europace</i> , 2016 , 18, 1679-1688	3.9	19	
159	Co-activation of nuclear factor- B and myocardin/serum response factor conveys the hypertrophy signal of high insulin levels in cardiac myoblasts. <i>Journal of Biological Chemistry</i> , 2014 , 289, 19585-98	5.4	19	
158	The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 14-38	7	19	
157	Mechanical prosthetic heart valves: Quality of anticoagulation and thromboembolic risk. The observational multicenter PLECTRUM study. <i>International Journal of Cardiology</i> , 2018 , 267, 68-73	3.2	18	
156	Prognostic Role of Cardiac Magnetic Resonance in Arrhythmogenic Right Ventricular Cardiomyopathy. <i>American Journal of Cardiology</i> , 2018 , 122, 1745-1753	3	18	
155	Quenching of intracellular ROS generation as a mechanism for oleate-induced reduction of endothelial activation and early atherogenesis. <i>Thrombosis and Haemostasis</i> , 2002 , 88, 335-44	7	18	
154	Pathways and Drugs in Pulmonary Arterial Hypertension - Focus on the Role of Endothelin Receptor Antagonists. <i>Cardiovascular Drugs and Therapy</i> , 2015 , 29, 469-79	3.9	17	
153	Pharmacological modulation of vascular inflammation in atherothrombosis. <i>Annals of the New York Academy of Sciences</i> , 2010 , 1207, 23-31	6.5	17	
152	Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe). <i>BMC Cardiovascular Disorders</i> , 2019 , 19, 165	2.3	16	
151	Non-Vitamin K Antagonist Oral Anticoagulants for Cardioversion in Atrial Fibrillation: An Updated Meta-analysis. <i>American Journal of Medicine</i> , 2017 , 130, 457-461	2.4	16	
150	Stroke prevention in atrial fibrillation: current status and near-future directions. <i>American Journal of Medicine</i> , 2011 , 124, 793-9	2.4	16	
149	Mid-term outcomes after percutaneous interventions in coronary bifurcations. <i>International Journal of Cardiology</i> , 2019 , 283, 78-83	3.2	16	
148	Grading of aortic stenosis severity: a head-to-head comparison between cardiac magnetic resonance imaging and echocardiography. <i>Radiologia Medica</i> , 2018 , 123, 643-654	6.5	15	
147	Stroke Prevention in Atrial Fibrillation: A Clinical Perspective on Trials of the Novel Oral Anticoagulants. <i>Cardiovascular Drugs and Therapy</i> , 2016 , 30, 201-14	3.9	15	
146	Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy - A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registries. <i>International Journal of Cardiology</i> , 2018 , 270, 160-166	3.2	15	
145	Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy. <i>Archives of Cardiovascular Diseases</i> , 2018 , 111, 74-84	2.7	14	

144	Cholesterol-lowering interventions and stroke: Insights from IMPROVE-IT. <i>Atherosclerosis</i> , 2016 , 248, 216-8	3.1	14
143	Transplantation of mesenchymal cells improves peripheral limb ischemia in diabetic rats. <i>Molecular Biotechnology</i> , 2014 , 56, 438-48	3	14
142	Nitrates and other nitric oxide donors in cardiology: current positioning and perspectives. <i>Cardiovascular Drugs and Therapy</i> , 2012 , 26, 55-69	3.9	14
141	Glucose metabolism, hyperosmotic stress, and reprogramming of somatic cells. <i>Molecular Biotechnology</i> , 2013 , 55, 169-78	3	14
140	Oral anticoagulant use in octogenarian European patients with atrial fibrillation: A subanalysis of PREFER in AF. <i>International Journal of Cardiology</i> , 2017 , 232, 98-104	3.2	13
139	Oxidative stress and vascular stiffness in hypertension: A renewed interest for antioxidant therapies?. <i>Vascular Pharmacology</i> , 2019 , 116, 45-50	5.9	13
138	Role and importance of ultrasound lung comets in acute cardiac care. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015 , 4, 103-12	4.3	13
137	The safety and efficacy of non-vitamin K antagonist oral anticoagulants in atrial fibrillation in the elderly. <i>International Journal of Cardiology</i> , 2018 , 265, 118-124	3.2	13
136	Bivalirudin for acute coronary syndromes: premises, promises and doubts. <i>Thrombosis and Haemostasis</i> , 2015 , 113, 698-707	7	13
135	The current role of anticoagulants in cardiovascular medicine. <i>Journal of Cardiovascular Medicine</i> , 2009 , 10, 595-604	1.9	13
134	Omega-3 fatty acids, atherogenesis, and endothelial activation. <i>Journal of Cardiovascular Medicine</i> , 2007 , 8 Suppl 1, S11-4	1.9	13
133	Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions	9.5	13
132	Thrombotic and hemorrhagic burden in women: Gender-related issues in the response to antithrombotic therapies. <i>International Journal of Cardiology</i> , 2019 , 286, 198-207	3.2	13
131	Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study. <i>Journal of Cardiovascular Medicine</i> , 2019 , 20, 97-104	1.9	13
130	PCSK9 and atherosclerosis: Looking beyond LDL regulation. <i>European Journal of Clinical Investigation</i> , 2021 , 51, e13459	4.6	13
129	Imaging of the vulnerable carotid plaque: Role of imaging techniques and a research agenda. <i>Neurology</i> , 2020 , 94, 922-932	6.5	12
128	Effects of Olive Oil on Blood Pressure: Epidemiological, Clinical, and Mechanistic Evidence. <i>Nutrients</i> , 2020 , 12,	6.7	12
127	Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation. <i>American Journal of Medicine</i> , 2016 , 129, 1117-1123.e2	2.4	12

126	Cell based mechanosensing in vascular patho-biology: More than a simple go-with the flow. <i>Vascular Pharmacology</i> , 2018 , 111, 7-14	5.9	12
125	CHADSVASc score and adverse outcomes in middle-aged individuals without atrial fibrillation. <i>European Journal of Preventive Cardiology</i> , 2019 , 26, 1987-1997	3.9	12
124	Platelet Indices and Risk of Death and Cardiovascular Events: Results from a Large Population-Based Cohort Study. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 1773-1784	7	11
123	Proteomic analysis of the secretome of adipose tissue-derived murine mesenchymal cells overexpressing telomerase and myocardin. <i>Journal of Molecular and Cellular Cardiology</i> , 2019 , 131, 171-	-1 78 8	11
122	Three-Dimensional Echographic Evaluation of Carotid Artery Disease. <i>Journal of Cardiovascular Echography</i> , 2018 , 28, 218-227	0.6	11
121	Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial. <i>Circulation</i> , 2020 , 141, 10-20	16.7	11
120	Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: A randomized clinical trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021 ,	1.5	11
119	History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. <i>American Heart Journal</i> , 2016 , 175, 175-83	4.9	10
118	Proton pump inhibitors and clopidogrel: an association to avoid?. <i>Internal and Emergency Medicine</i> , 2014 , 9, 11-22	3.7	10
117	Aquaporin-1 and sodium-hydrogen exchangers as pharmacological targets in diabetic atherosclerosis. <i>Current Drug Targets</i> , 2015 , 16, 361-5	3	10
116	Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, f30-f39	6.4	10
115	The JAK-STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms. <i>European Heart Journal</i> , 2021 , 42, 4389-4400	9.5	10
114	Ponatinib Induces Vascular Toxicity through the Notch-1 Signaling Pathway. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	9
113	Simulated hyperglycemia impairs insulin signaling in endothelial cells through a hyperosmolar mechanism. <i>Vascular Pharmacology</i> , 2020 , 130, 106678	5.9	9
112	The acute impact of high-dose lipid-lowering treatment on endothelial progenitor cells in patients with coronary artery disease-The REMEDY-EPC early substudy. <i>PLoS ONE</i> , 2017 , 12, e0172800	3.7	9
111	Determinants of left atrium thrombi in scheduled cardioversion: an ENSURE-AF study analysis. <i>Europace</i> , 2019 , 21, 1633-1638	3.9	9
110	Receiver operating characteristic (ROC) curves and the definition of threshold levels to diagnose coronary artery disease on electrocardiographic stress testing. Part II: the use of ROC curves in the choice of electrocardiographic stress test markers of ischaemia. <i>Journal of Cardiovascular Medicine</i> ,	1.9	9
109	2008 , 9, 22-31 Nutrients and gene expression. <i>World Review of Nutrition and Dietetics</i> , 2004 , 93, 99-133	0.2	9

108	Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease. <i>Circulation</i> , 2021 , 144, 1323-1343	16.7	9
107	Empagliflozin reduces the senescence of cardiac stromal cells and improves cardiac function in a murine model of diabetes. <i>Journal of Cellular and Molecular Medicine</i> , 2020 , 24, 12331-12340	5.6	9
106	Cholesterol Lowering and Stroke: No Longer Room for Pleiotropic Effects of Statins - Confirmation from PCSK9 Inhibitor Studies. <i>American Journal of Medicine</i> , 2020 , 133, 95-99.e6	2.4	9
105	The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and design. <i>Clinical Cardiology</i> , 2019 , 42, 1147-1154	3.3	8
104	Controversial Relationship Between Renin-Angiotensin System Inhibitors and Severity of COVID-19: Announcing a Large Multicentre Case-Control Study in Italy. <i>Hypertension</i> , 2020 , 76, 312-313	8.5	8
103	From short-term blood pressure variability to atherosclerosis: Relative roles of vascular stiffness and endothelial dysfunction. <i>Journal of Clinical Hypertension</i> , 2020 , 22, 1218-1227	2.3	8
102	The WOEST study: Critical considerations and applicability. <i>Cor Et Vasa</i> , 2014 , 56, e254-e258	0.3	8
101	Mortality Prediction of the CHADS-VASc Score, the HAS-BLED Score, and Their Combination in Anticoagulated Patients with Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	8
100	COVID-19-related cardiac complications from clinical evidences to basic mechanisms: opinion paper of the ESC Working Group on Cellular Biology of the Heart. <i>Cardiovascular Research</i> , 2021 , 117, 2148-21	60 9	8
99	Determinants of subacute response to clopidogrel: relative impact of CYP2C19 genotype and PGE1/adenylate cyclase signalling. <i>Thrombosis Research</i> , 2015 , 136, 308-14	8.2	7
98	Sodium-hydrogen exchangers (NHE) in human cardiovascular diseases: interfering strategies and their therapeutic applications. <i>Vascular Pharmacology</i> , 2013 , 59, 127-30	5.9	7
97	Is Complete Revascularisation Mandated for all Patients with Multivessel Coronary Artery Disease?. <i>Interventional Cardiology Review</i> , 2018 , 13, 45-50	4.2	7
96	Clinical use of aspirin in ischemic heart disease: past, present and future. <i>Current Pharmaceutical Design</i> , 2012 , 18, 5215-23	3.3	7
95	Transcriptome-based identification of new anti-inflammatory and vasodilating properties of the n-3 fatty acid docosahexaenoic acid in vascular endothelial cell under proinflammatory conditions [corrected]. <i>PLoS ONE</i> , 2015 , 10, e0129652	3.7	7
94	Coronary Artery Anomalies. <i>Circulation</i> , 2021 , 144, 983-996	16.7	7
93	Gull ESC 2016 sobre el diagnilico y tratamiento de la fibrilacifi auricular, desarrollada en colaboracifi con la EACTS. <i>Revista Espanola De Cardiologia</i> , 2017 , 70, 50.e1-50.e84	1.5	6
92	Edoxaban in Atrial Fibrillation and Venous Thromboembolism-Ten Key Questions and Answers: A Practical Guide. <i>Advances in Therapy</i> , 2017 , 34, 620-637	4.1	6
91	Aspirin and the Primary Prevention of Cardiovascular Diseases: An Approach Based on Individualized, Integrated Estimation of Risk. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2017, 24, 331-339	2.9	6

(2020-2016)

90	Targeting thrombin long-term after an acute coronary syndrome: Opportunities and challenges. <i>Vascular Pharmacology</i> , 2016 , 81, 1-14	5.9	6
89	Long-term engraftment and angiogenic properties of lentivirally transduced adipose tissue-derived stromal cells. <i>Molecular Biotechnology</i> , 2013 , 54, 13-24	3	6
88	Impact of statin therapy intensity on endothelial progenitor cells after percutaneous coronary intervention in diabetic patients. The REMEDY-EPC late study. <i>International Journal of Cardiology</i> , 2017 , 244, 112-118	3.2	6
87	Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. nonselective COX-2 inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2010 , 69, 303-6	3.8	5
86	A case report of multisite arterial thrombosis in a patient with coronavirus disease 2019 (COVID-19). European Heart Journal - Case Reports, 2021 , 5, ytaa339	0.9	5
85	Rosuvastatin for Reduction of Myocardial Damage during Coronary Angioplasty - the Remedy Trial. <i>Cardiovascular Drugs and Therapy</i> , 2016 , 30, 465-472	3.9	5
84	Relation of Stroke and Bleeding Risk Profiles to Efficacy and Safety of Edoxaban for Cardioversion of Atrial Fibrillation (from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation [ENSURE-AF] Study). <i>American Journal of Cardiology</i> , 2018 , 121, 193-198	3	5
83	Ultra-Sensitive Copeptin and Cardiac Troponin in Diagnosing Non-ST-Segment Elevation Acute Coronary SyndromesThe COPACS Study. <i>American Journal of Medicine</i> , 2016 , 129, 105-14	2.4	4
82	The co-predictive value of a cardiovascular score for CV outcomes in diabetic patients with no atrial fibrillation. <i>Diabetes/Metabolism Research and Reviews</i> , 2019 , 35, e3145	7.5	4
81	Thromboembolic and bleeding risk in obese patients with atrial fibrillation according to different anticoagulation strategies. <i>International Journal of Cardiology</i> , 2020 , 318, 67-73	3.2	4
80	Co-expression of glycosylated aquaporin-1 and transcription factor NFAT5 contributes to aortic stiffness in diabetic and atherosclerosis-prone mice. <i>Journal of Cellular and Molecular Medicine</i> , 2020 , 24, 2857-2865	5.6	4
79	Aspirin for primary prevention of cardiovascular disease: Advice for a decisional strategy based on risk stratification. <i>Anatolian Journal of Cardiology</i> , 2020 , 23, 70-78	0.8	4
78	Aspirin Therapy for Primary Prevention: The Case for Continuing Prescribing to Patients at High Cardiovascular Risk-A Review. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 199-206	7	4
77	Endothelial Dysfunction, Fibrinolytic Activity, and Coagulation Activity in Patients With Atrial Fibrillation According to Type II Diabetes Mellitus Status. <i>American Journal of Cardiology</i> , 2020 , 125, 75	1 <i>-</i> 758	4
76	Optimal Antithrombotic Treatment of Patients with Atrial Fibrillation Early after an Acute Coronary Syndrome-Triple Therapy, Dual Antithrombotic Therapy with an Anticoagulant Dr., Rather, Temporary Dual Antiplatelet Therapy?. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	4
75	ST segment/heart rate hysteresis improves the diagnostic accuracy of ECG stress test for coronary artery disease in patients with left ventricular hypertrophy. <i>European Journal of Preventive Cardiology</i> , 2016 , 23, 1632-9	3.9	4
74	Aspirin in heart failure: don't throw the baby (aspirin) out with the bathwater. <i>European Journal of Heart Failure</i> , 2017 , 19, 1089-1094	12.3	3
73	Transplantation of telomerase/myocardin-co-expressing mesenchymal cells in the mouse promotes myocardial revascularization and tissue repair. <i>Vascular Pharmacology</i> , 2020 , 135, 106807	5.9	3

72	Commentary: Temporarily omitting oral anticoagulants early after stenting for acute coronary syndromes patients with atrial fibrillation. <i>International Journal of Cardiology</i> , 2020 , 318, 82-85	3.2	3
71	Isolated Exercise-Induced Pulmonary Hypertension Associates with Higher Cardiovascular Risk in Scleroderma Patients. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	3
70	Potential roles of vessel wall heparan sulfate proteoglycans in atherosclerosis. <i>Vascular Pharmacology</i> , 2014 , 60, 49-51	5.9	3
69	New anticoagulants for atrial fibrillation. <i>Journal of Cardiovascular Medicine</i> , 2009 , 10, 446-53	1.9	3
68	Association of the European Society of Cardiology echocardiographic probability grading for pulmonary hypertension with short and mid-term clinical outcomes after heart valve surgery. <i>Vascular Pharmacology</i> , 2020 , 125-126, 106648	5.9	3
67	Left Ventricular Size Predicts Clinical Benefit After Percutaneous Mitral Valve Repair for Secondary Mitral Regurgitation: A Systematic Review and Meta-Regression Analysis. <i>Cardiovascular Revascularization Medicine</i> , 2020 , 21, 857-864	1.6	3
66	Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and atrial thrombosis: An appraisal of current evidence. <i>Archives of Cardiovascular Diseases</i> , 2020 , 113, 642-651	2.7	3
65	Reclassification, Thromboembolic, and Major Bleeding Outcomes Using Different Estimates of Renal Function in Anticoagulated Patients With Atrial Fibrillation: Insights From the PREFER-in-AF and PREFER-in-AF Prolongation Registries. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021 ,	5.8	3
64	Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry. <i>Internal and Emergency Medicine</i> , 2021 , 16, 591-599	3.7	3
63	Antithrombotic Management in Patients with Prosthetic Valves246-271		3
62	Failure in evoking the trigeminal cardiac reflex by mandibular stretching in healthy volunteers. <i>Archives Italiennes De Biologie</i> , 2015 , 153, 25-36	1.1	3
61	Intracardiac thrombi during warfarin anticoagulation - A case report and a brief literature review. <i>Cor Et Vasa</i> , 2017 , 59, e277-e281	0.3	2
60	Where are clots in atrial fibrillation? Did we have the wrong assumptions over the last decades?. <i>Europace</i> , 2020 , 22, 845-846	3.9	2
59	Antithrombotic treatment strategies after PCI. <i>Lancet, The</i> , 2020 , 395, 865	40	2
58	Effect of concomitant antiplatelet agents on clinical outcomes in the edoxaban vs warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomized trial. <i>Clinical Research in Cardiology</i> , 2020 , 109, 1374-1380	6.1	2
57	Should We Continue Assessing Glomerular Filtration Rate with the Cockroft-Gault Formula in NOAC-Treated Patients? The Magnitude of the Problem. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	2
56	Benefit of dual antithrombotic therapy with direct oral anticoagulants in patients with atrial fibrillation undergoing percutaneous coronary intervention: a systematic review and metaanalysis of randomized clinical trials. <i>Internal and Emergency Medicine</i> , 2020 , 15, 1093-1104	3.7	2
55	Coronary computed tomography angiography, ECG stress test and nuclear imaging as sources of false-positive results in the detection of coronary artery disease. <i>Journal of Cardiovascular Medicine</i> , 2018 , 19 Suppl 1, e133-e138	1.9	2

54	Atherogenesis and Diabetes: Focus on Insulin Resistance and Hyperinsulinemia. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012 , 65, 309-313	0.7	2
53	Aspirin for primary cardiovascular prevention: why the wonder drug should not be precipitously dismissed. <i>Polish Archives of Internal Medicine</i> , 2020 , 130, 121-129	1.9	2
52	ST-segment/heart rate hysteresis improves the exercise testing accuracy for coronary artery detection in asymptomatic patients with severe aortic stenosis. <i>Journal of Cardiovascular Medicine</i> , 2021 , 22, 323-325	1.9	2
51	Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 ,	6.4	2
50	The European Heart Journal: leading the fight to reduce the global burden of cardiovascular disease. <i>European Heart Journal</i> , 2020 , 41, 3113-3116	9.5	2
49	Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials. <i>JAMA Network Open</i> , 2020 , 3, e2015943	10.4	2
48	Clustering of blood cell count abnormalities and future risk of death. <i>European Journal of Clinical Investigation</i> , 2021 , 51, e13562	4.6	2
47	Telomerase/myocardin expressing mesenchymal cells induce survival and cardiovascular markers in cardiac stromal cells undergoing ischaemia/reperfusion. <i>Journal of Cellular and Molecular Medicine</i> , 2021 , 25, 5381-5390	5.6	2
46	Insulin-treated versus noninsulin-treated diabetes and risk of ischemic stroke in patients with atrial fibrillation. <i>Vascular Pharmacology</i> , 2021 , 136, 106809	5.9	2
45	Pre-treatment high-sensitivity troponin T for the short-term prediction of cardiac outcomes in patients on immune checkpoint inhibitors. <i>European Journal of Clinical Investigation</i> , 2021 , 51, e13400	4.6	2
44	Safety and Effectiveness of Edoxaban in Atrial Fibrillation Patients in Routine Clinical Practice: One-Year Follow-Up from the Global Noninterventional ETNA-AF Program. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
43	Myocardial revascularization in ischaemic cardiomyopathy: routine practice vs. scientific evidence. <i>European Heart Journal</i> , 2021 ,	9.5	2
42	RIvaroxaban in mitral stenosis (RISE MS): A pilot randomized clinical trial <i>International Journal of Cardiology</i> , 2022 ,	3.2	2
41	The new ACCF/AHA guidelines on the treatment of dyslipidemia: pros. <i>Internal and Emergency Medicine</i> , 2015 , 10, 115-7	3.7	1
40	Comparison of Dabigatran Plus a P2Y Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI. <i>American Journal of Medicine</i> , 2020 , 133, 1302-1312	2.4	1
39	PrevenTion of contrast-inducEd nephropAThy with urinE alkalinization: the TEATE study design. <i>Journal of Cardiovascular Medicine</i> , 2020 , 21, 65-72	1.9	1
38	Oral anticoagulants for atrial fibrillation and acute coronary syndrome with or without stenting. <i>Journal of Cardiovascular Medicine</i> , 2018 , 19 Suppl 1, e40-e45	1.9	1
37	Is there an 'atherosclerotic continuum' from angina with unobstructed coronary arteries to MINOCA? Reply. <i>European Heart Journal</i> , 2019 , 40, 1988	9.5	1

36	Reprint of P otential roles of vessel wall heparan sulfate proteoglycans in atherosclerosis <i>Vascular Pharmacology</i> , 2014 , 62, 120-122	5.9	1
35	Opportunities and challenges in nutrigenetics/nutrigenomics and health. <i>Journal of Nutrigenetics and Nutrigenomics</i> , 2010 , 3, 137-43		1
34	Sex-related differential susceptibility to ponatinib cardiotoxicity and differential modulation of the Notch1 signalling pathway in a murine model <i>Journal of Cellular and Molecular Medicine</i> , 2022 ,	5.6	1
33	Sodium-glucose cotransporter type 2 inhibitors prevent ponatinib-induced endothelial senescence and disfunction: A potential rescue strategy. <i>Vascular Pharmacology</i> , 2021 , 142, 106949	5.9	1
32	The Vessels-Bone Axis: Iliac Artery Calcifications, Vertebral Fractures and Vitamin K from VIKI Study. <i>Nutrients</i> , 2021 , 13,	6.7	1
31	Challenges in ischaemic heart disease: not sleeping enough, not brushing your teeth, and skipping breakfast-three ways of increasing your risk of myocardial infarction?. <i>European Heart Journal Supplements</i> , 2020 , 22, L57-L60	1.5	1
30	Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas. <i>Open Heart</i> , 2021 , 8,	3	1
29	Factors associated with the dosing of edoxaban for stroke prevention in patients with atrial fibrillation from South Korea and Taiwan: 1-year data from the Global ETNA-AF Program. <i>Journal of the Chinese Medical Association</i> , 2021 , 84, 485-490	2.8	1
28	Connexin 43 and Connexin 26 Involvement in the Ponatinib-Induced Cardiomyopathy: Sex-Related Differences in a Murine Model. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
27	Many Good Reasons to Switch from Vitamin K Antagonists to Non-Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
26	How safe are non-vitamin K antagonist oral anticoagulants in atrial fibrillation?. <i>European Heart Journal Supplements</i> , 2016 , 18, I1-I6	1.5	1
25	All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT. <i>Data in Brief</i> , 2016 , 7, 1541-50	1.2	1
24	Spontaneous conversion in patients with non-valvular atrial fibrillation planned for electrical cardioversion: A subanalysis of the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion Of Atrial Fibrillation (ENSURE-AF) trial. <i>American Heart Journal</i> , 2019 , 209, 131-135	4.9	1
23	Is coronary flow velocity reserve just a marker of a higher atherosclerotic burden?. <i>European Heart Journal</i> , 2021 , 42, 1444-1445	9.5	1
22	Is there equivalence between PCI and CABG surgery in long-term survival of patients with diabetes? Importance of interpretation biases and biological plausibility. <i>European Heart Journal</i> , 2021 ,	9.5	1
21	Eighty years of oral anticoagulation: Learning from history. Vascular Pharmacology, 2021 , 141, 106918	5.9	1
20	New cardiovascular risk factors: homocysteine and vitamins involved in homocysteine metabolism. <i>Italian Heart Journal: Official Journal of the Italian Federation of Cardiology</i> , 2004 , 5 Suppl 6, 19S-24S		1
19	Comparing TEE- vs Non-TEE-guided cardioversion of atrial fibrillation: The ENSURE-AF trial. <i>European Journal of Clinical Investigation</i> , 2020 , 50, e13221	4.6	O

18	The nomenclature vagaries for the clinical manifestations of myocardial ischemic syndromes - A call to action. <i>International Journal of Cardiology</i> , 2020 , 304, 5-7	3.2	О
17	Patient Preferences of Low-Dose Aspirin for Cardiovascular Disease and Colorectal Cancer Prevention in Italy: A Latent Class Analysis. <i>Patient</i> , 2021 , 14, 661-672	3.7	O
16	The Nutrigenetics of Cardiovascular Disease 2020 , 355-360		O
15	Interpreting myocardial infarction analyses in ISCHEMIA: separating facts from fallacy. <i>European Heart Journal</i> , 2021 , 42, 2986-2989	9.5	O
14	Exercise-induced pulmonary hypertension in HIV patients: Association with poor clinical and immunological status. <i>Vascular Pharmacology</i> , 2021 , 139, 106888	5.9	О
13	Left Atrial Remodeling and Stroke in Patients With Sinus Rhythm and Normal Ejection Fraction: ARIC-NCS <i>Journal of the American Heart Association</i> , 2022 , 11, e024292	6	О
12	Do we need P2Y12 inhibitor pretreatment in non-ST elevation acute coronary syndrome?. <i>Revista Portuguesa De Cardiologia</i> , 2016 , 35, 319-21	1	
11	Management of pregnant women with artificial heart valves: inconsistency in ESC publications: reply. <i>European Heart Journal</i> , 2007 , 28, 2419-2420	9.5	
10	Extent and progression of atherosclerosis in carotid and subclavian arteries: the Carotid Artery Subclavian Artery study. <i>Journal of Cardiovascular Medicine</i> , 2021 , 22, 652-656	1.9	
9	Excessive Orthostatic Changes in Blood Pressure Are Associated With Incident Heart Failure in Older Men: A Prospective Analysis From the BRHS. <i>Hypertension</i> , 2021 , 77, 1481-1489	8.5	
8	A highly-detailed anatomical study of normal pericardial structures as revealed by in-vivo computed tomography and magnetic resonance images and ex-vivo novel 3D reconstructions from Visible Human Server. <i>Imaging</i> , 2021 , 13, 1-12	0.3	
7	Do we need P2Y12 inhibitor pretreatment in non-ST elevation acute coronary syndrome?. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2016 , 35, 319-321	О	
6	Why include the humanities in medical studies?. Internal and Emergency Medicine, 2020, 15, 523-524	3.7	
5	Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and The Netherlands: insights from the ETNA-AF-Europe study. <i>Acta Cardiologica</i> , 2021 , 76, 431-439	0.9	
4	Antiplatelet therapy in patients with acute coronary syndromes and thrombocytopaenia: awaiting for evidence. <i>European Heart Journal - Case Reports</i> , 2021 , 5, ytaa577	0.9	
3	Low-dose aspirin in the primary prevention of cardiovascular disease: how to balance the benefits and the risks. <i>Italian Heart Journal: Official Journal of the Italian Federation of Cardiology</i> , 2003 , 4, 228-3	31	
2	The non-vitamin K antagonist oral anticoagulants and heparin-induced prolongation of the activated coagulation time <i>Vascular Pharmacology</i> , 2022 , 106994	5.9	
1	Response to "non-vitamin K antagonist oral anticoagulants (NOACs) in preventing thromboembolism in atrial fibrillation patients with moderate to severe mitral stenosis: Results from a pilot trial" <i>International Journal of Cardiology</i> , 2022 ,	3.2	